KESIMPTA (Ofatumumab): An Overview for Relapsing Multiple Sclerosis

KESIMPTA (ofatumumab) is a prescription medication used to treat relapsing forms of multiple sclerosis (RMS) in adults. As a targeted therapy, 


KESIMPTA (Ofatumumab): An Overview for Relapsing Multiple Sclerosis

KESIMPTA (ofatumumab) is a prescription medication used to treat relapsing forms of multiple sclerosis (RMS) in adults. As a targeted therapy, it works differently from some other MS treatments by specifically targeting certain immune cells. Understanding how KESIMPTA works, its administration, and potential considerations is crucial for those exploring treatment options for MS.

What is KESIMPTA (Ofatumumab)?

Ofatumumab, marketed as KESIMPTA, is a human monoclonal antibody. It belongs to a class of medications known as B-cell depleting therapies. Its primary action is to bind to a protein called CD20, which is found on the surface of B-lymphocytes (a type of white blood cell). By targeting and reducing these CD20-positive B-cells, KESIMPTA is thought to reduce inflammation and damage in the brain and spinal cord, which are characteristic of multiple sclerosis.

While the exact role of B-cells in MS is still being researched, it's understood that they play a significant part in the autoimmune attack that leads to MS symptoms and disease progression.

Indications: Who is KESIMPTA for?

KESIMPTA is approved for the treatment of relapsing forms of multiple sclerosis (RMS) in adults. This includes:


  • Clinically Isolated Syndrome (CIS): A first episode of neurological symptoms caused by inflammation and demyelination in the central nervous system.

  • Relapsing-Remitting MS (RRMS): The most common form of MS, characterized by clearly defined attacks (relapses) followed by periods of partial or complete recovery (remissions).

  • Active Secondary Progressive MS (SPMS): A form of MS that initially begins as RRMS and then transitions to a more steadily progressive course, often with continued relapses.

It is important to note that KESIMPTA is not indicated for primary progressive MS (PPMS) or non-active secondary progressive MS.

How KESIMPTA is Administered

KESIMPTA is administered as a subcutaneous injection, meaning it's injected just under the skin. It comes in a pre-filled pen, designed for easy self-administration at home after appropriate training from a healthcare professional.

Dosing Schedule

The typical dosing schedule involves:


  • An initial dose.

  • Followed by doses at week 1 and week 2.

  • After the initial three doses, KESIMPTA is typically administered once a month.

Healthcare providers will provide specific instructions on how to prepare and administer the injection, and it's vital to follow these instructions precisely.

Potential Benefits of KESIMPTA

Clinical studies have demonstrated KESIMPTA's efficacy in managing relapsing forms of MS. Key potential benefits include:


  • Reducing the frequency of relapses.

  • Slowing the progression of disability.

  • Decreasing the number of new or enlarging lesions in the brain as seen on MRI scans.

Individual responses to KESIMPTA can vary, and its benefits should be weighed against potential risks in consultation with a healthcare provider.

Important Safety Information and Side Effects

Like all medications, KESIMPTA can cause side effects. It's crucial to discuss any concerns with your doctor. Common side effects may include:


  • Injection-related reactions (e.g., redness, pain, swelling, itching at the injection site). These are generally mild to moderate and tend to decrease over time.

  • Upper respiratory tract infections.

  • Headache.

More serious side effects are possible and require immediate medical attention. These can include, but are not limited to:


  • Serious infections: Due to its effect on the immune system, KESIMPTA can increase the risk of serious infections.

  • Progressive Multifocal Leukoencephalopathy (PML): A rare but serious brain infection that can lead to severe disability or death.

  • Hepatitis B virus (HBV) reactivation: If you have had hepatitis B, the virus could become active again.

  • Low immunoglobulin levels: KESIMPTA can lead to reductions in immunoglobulin levels, which can increase the risk of infection.

Before starting KESIMPTA, your doctor will likely screen you for certain infections, including Hepatitis B. It's essential to inform your doctor about all your medical conditions, medications you are taking, and any allergies.

Consulting Your Healthcare Professional

This information provides a general overview of KESIMPTA (ofatumumab) and is not a substitute for professional medical advice. Deciding on the most appropriate MS treatment is a complex process that should always involve a thorough discussion with your neurologist or healthcare team. They can assess your individual health profile, the specifics of your MS, and help determine if KESIMPTA is a suitable treatment option for you.